



The Stem Cell Specialist.

STEMLIFE BERHAD

(Company No: 566770-D)

Incorporated in Malaysia

QUARTERLY REPORT

FOR THE FIRST QUARTER ENDED 31 MARCH 2010

(The figures have not been audited)

CONDENSED CONSOLIDATED INCOME STATEMENT

	Individual Quarter		Cumulative Quarter	
	Current Year Quarter 31.03.2010 (RM'000)	Preceding Year Quarter 31.03.2009 (RM'000)	Current Year To Date 31.03.2010 (RM'000)	Preceding Year Corresponding Period 31.03.2009 (RM'000)
Revenue	3,595	2,831	3,595	2,831
Costs of Sales	(3,130)	(2,552)	(3,130)	(2,552)
Gross Profit	465	279	465	279
Other Income	309	147	309	147
Administrative Expenses	(1,221)	(1,474)	(1,221)	(1,474)
Loss from Operations	(447)	(1,048)	(447)	(1,048)
Share of Associated Company's Results	(45)	196	(45)	196
Loss Before Taxation	(492)	(852)	(492)	(852)
Taxation	(27)	(45)	(27)	(45)
Loss After Taxation	(519)	(897)	(519)	(897)
Minority Interests	41	48	41	48
Loss Attributable to Shareholders	(478)	(849)	(478)	(849)
Basic loss per share (“(LPS)”) (sen.)	(0.29)	(0.51)	(0.29)	(0.51)
Diluted - LPS (sen)	(0.29)	(0.51)	(0.29)	(0.51)
Effective Tax Rate (%)	n/a	n/a	n/a	n/a

The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2009.

STEMLIFE BERHAD

(Company No: 566770-D)

Incorporated in Malaysia

QUARTERLY REPORT

FOR THE FIRST QUARTER ENDED 31 MARCH 2010

(The figures have not been audited)

CONDENSED CONSOLIDATED BALANCE SHEET

	As at End of Current Quarter 31.03.2010 (RM'000)	Audited As at Preceding Financial Year Ended 31.12.2009 (RM'000)
Non-Current Assets		
Property, Plant and Equipment	5,872	5,983
Investments	5,643	5,688
Net Non-Current Assets	11,515	11,671
Current Assets		
Inventories	566	646
Trade Receivables	8,192	6,929
Other Receivables and Deposits	809	771
Short Term Investment	3,000	3,000
Tax Recoverables	137	137
Cash and Bank Balances	40,308	38,973
	53,012	50,456
Current Liabilities		
Trade Payables	624	331
Advance Payment	29,186	25,292
Other Payables and Accruals	467	1,735
Taxation	-	-
	30,277	27,358
Net Current Assets	22,735	23,098
NET ASSETS	34,250	34,769
Financed by:		
Share capital	16,500	16,500
Reserves	16,141	16,619
Shareholders' Funds	32,641	33,119
Minority Interest	1,609	1,650
TOTAL EQUITY	34,250	34,769
Net Asset per Share Attributable to Ordinary Equity Holders of the Parent (sen)	19.78	20.07

The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2009.

STEMLIFE BERHAD

(Company No: 566770-D)

Incorporated in Malaysia

QUARTERLY REPORT

FOR THE FIRST QUARTER ENDED 31 MARCH 2010

(The figures have not been audited)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Issued and Paid- up Share Capital RM'000	Share Premium RM'000	Exchange Reserve RM'000	Unappropriated Profit RM'000	Total RM'000	Minority Interest RM'000	Total Equity RM'000
Balance as at 1 January 2010	16,500	11,698	51	4,870	33,119	1,650	34,769
Net Loss for the Period	-	-	-	(478)	(478)	-	(478)
Minority Interest	-	-	-	-	-	(41)	(41)
Balance as at 31 March 2010	16,500	11,698	51	4,392	32,641	1,609	34,250
Balance as at 1 January 2009	16,500	11,698	(3)	9,340	37,535	1,862	39,397
Net Loss for the Period	-	-	-	(849)	(849)	-	(849)
Minority Interest	-	-	-	-	-	(48)	(48)
Balance as at 31 March 2009	16,500	11,698	(3)	8,491	36,686	1,814	38,500

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2009.

STEMLIFE BERHAD

(Company No: 566770-D)

Incorporated in Malaysia

QUARTERLY REPORT

FOR THE FIRST QUARTER ENDED 31 MARCH 2010

(The figures have not been audited)

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

	Current Year To Date Ended 31.03.2010 (RM'000)	Corresponding Year To Date Ended 31.03.2009 (RM'000)
CASH FLOWS FROM OPERATING ACTIVITIES		
<i>Cash Inflow</i>		
Receipts from Customers	6,226	5,914
<i>Cash Outflow</i>		
Payment to Suppliers	(2,602)	(1,995)
Payment for Taxation	(27)	(45)
Payment for Overheads	(2,361)	(1,751)
	(4,990)	(3,791)
Net Cash Flow from Operating Activities	1,236	2,123
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of Properties, Plants and Equipments	(208)	(150)
CASH FLOW FROM FINANCING ACTIVITIES		
<i>Cash Inflow</i>		
Amount Owing by Associated Company	-	4
Other Income	309	147
	309	151
<i>Cash Outflow</i>		
Amount Owing by Associated Company	(2)	-
Net Cash Flow from Financing Activities	307	151
NET INCREASE IN CASH AND CASH EQUIVALENTS	1,335	2,124
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	41,973	36,941
CASH AND CASH EQUIVALENTS AT END OF PERIOD	43,308	39,065

The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2009.



The Stem Cell Specialist.

STEMLIFE BERHAD

(Company No: 566770-D)

Incorporated in Malaysia

QUARTERLY REPORT FOR THE FIRST QUARTER ENDED 31 MARCH 2010 (The figures have not been audited)

NOTES TO THE INTERIM FINANCIAL STATEMENTS

PART A – EXPLANATORY NOTES PURSUANT TO FRS 134

A 1. BASIS OF PREPARATION

The unaudited interim financial statements have been prepared in accordance with the FRS 134 Interim Financial Reporting issued by the Malaysian Accounting Standards Board and Part K, Rule 9.22 (Appendix 9B) of the Listing Requirements of the Bursa Malaysia Securities Berhad (“Securities Exchange”) for the ACE Market (formerly known as the MESDAQ Market).

The unaudited interim financial report should be read in conjunction with the audited financial statements of StemLife and its subsidiary and associated companies (“the Group”) for the financial year ended 31 December 2009. These explanatory notes attached provide an explanation of events and transactions that are significant for an understanding of the changes in the financial position and performance of the Group since the year ended 31 December 2009.

A 2. CHANGES IN ACCOUNTING POLICIES

The significant accounting policies adopted are consistent with those of the audited financial statements for the year ended 31 December 2009.

The Group has not adopted FRS 130 Financial Instruments: Recognition and Measurement as its effective date has been deferred.

A 3. Auditors’ Report on Preceding Annual Financial Statements

The auditors’ report on the financial statements for the financial year ended 31 December 2009 was not qualified.

A 4. Seasonal and Cyclical Factors

The Group’s business operation results were not affected by any seasonal or cyclical factors.

A 5. Unusual Items Affecting Assets, Liabilities, Equity, Net Income or Cash Flow

There were no unusual items affecting the assets, liabilities, equity, net income or cash flow during the current financial quarter under review, that are unusual by reason of their nature, size or incidence.

A 6. Changes in Estimates

There were no changes in estimates of amounts reported in prior financial years, which have a material effect on the current financial quarter under review.



The Stem Cell Specialist.

STEMLIFE BERHAD

(Company No: 566770-D)

Incorporated in Malaysia

A 7. Debt and Equity Securities

There were no issuance, cancellation, repurchase, resale and repayment of debts and equity securities for the current financial quarter under review.

A 8. Dividends Paid

There were no dividends paid in the current financial quarter.

A 9. Segmental Information

The Group operates predominantly in Malaysia and is principally involved in the provision of stem cell banking services. As such, the financial information by geographical and industry segments of the Group's operations are not available for presentation.

A 10. Valuation of Property, Plant and Equipment

There has been no valuation on any of the Group's property, plant and equipment during the current financial quarter under review.

A 11. Subsequent Events

There were no material events subsequent to the end of the current financial quarter under review that has not been reflected.

A 12. Changes in the Composition of the Group

There are no changes in the composition of the Group during the current financial quarter under review.

A 13. Changes in Contingent Liabilities or Contingent Assets

There were no changes in the contingent liabilities or contingent assets since the last annual balance sheet date as at 31 December 2009.



The Stem Cell Specialist.

STEMLIFE BERHAD

(Company No: 566770-D)

Incorporated in Malaysia

QUARTERLY REPORT

FOR THE FIRST QUARTER ENDED 31 MARCH 2010

(The figures have not been audited)

NOTES TO THE INTERIM FINANCIAL STATEMENTS

PART B – EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF THE ACE MARKET

B 1. PERFORMANCE REVIEW

The Group posted revenue of RM3.60 million for the financial quarter under review (1Q10) against RM2.83 million in the preceding year corresponding quarter (1Q09). This represents an increase of 27.21%, mainly due to the higher number of deliveries in 1Q10 as compared to 1Q09 and increase in annual storage fees recognised in 1Q10 as compared to 1Q09, the result of a higher cumulative number of storage cases in 1Q10 against 1Q09.

Gross profit for 1Q10 was RM0.47 million as compared to 1Q09 of RM0.28 million, an increase of RM190K. The increase is primarily due to a lower cost of sales percentage in 1Q10 as compared to 1Q09 and increase in annual storage fees recognised in 1Q10 as compared to 1Q09.

The Group registered a loss after tax (LAT) for the quarter under review of approximately RM0.52 million compared to a loss after tax (LAT) of RM0.90 million in 1Q09, a decrease of approximately RM0.38 million. The decrease was primarily due to lower administrative expenses in 1Q10 as compared to 1Q09.

B 2. COMPARISON WITH PRECEDING QUARTER'S RESULTS

	1Q 2010	4Q 2009
	RM'000	RM'000
Revenue	3,595	4,971
Loss Before Tax (LBT)	(492)	(2,671)
Loss After Tax and Minority Interests (LATMI)	(478)	(2,565)

For the quarter under review, the Group recorded a revenue of RM3.60 million compared to RM4.97 million recorded in the preceding quarter (4Q09) representing a decrease of 27.68%. This is mainly due to the lower number of deliveries in 1Q10 as compared to 4Q09 and higher discount given on the stem cell banking enrolment and storage fees in the current quarter as compared to 4Q09. The Group registered a LBT of RM0.49 million as compared to a LBT of RM2.67 million recorded in the preceding quarter and a LATMI of RM0.48 million against a LATMI of RM2.57 million in the preceding quarter. The LATMI in 4Q09 was mainly due to the impairment charge of RM2.47 million and provision of bad debts of RM0.78 million. Excluding the impairment charge and provision of bad debts, the Group would register a PBT of RM0.58 million and a PATMI of RM0.69 million in 4Q09.



The Stem Cell Specialist.

STEMLIFE BERHAD
(Company No: 566770-D)
Incorporated in Malaysia

B 3. PROSPECTS OF THE GROUP

The Directors of StemLife are of the opinion that the Group's results for the financial year ending 31 December 2010 will be tested in view of the current uncertainty in the global economy.

B 4. VARIANCE OF ACTUAL AND FORECAST PROFIT

The Group did not issue any profit forecast for the financial period or year ending 31 December 2010 and therefore information on variance from profit forecast is not applicable.

B 5. TAXATION

The taxation figures are as follows:

	Current Quarter (RM'000)	Cumulative Year to Date (RM'000)
Estimated current tax payable	27	27

The statutory corporate income tax rate applicable to StemLife is 26%. However, the company's income which is mainly derived from approved BioNexus activities i.e. involving its cord blood and peripheral blood stem cells banking activities, are not subjected to income tax. The income tax payable recorded for the period is a result of other income and profits of other subsidiaries which are subjected to Malaysian and Thailand corporate income tax.

B 6. SALE OF UNQUOTED INVESTMENTS AND/OR PROPERTIES

There were no sales of any unquoted investments and/or properties for the current financial quarter and financial year to date.

B 7. PURCHASE OF QUOTED SECURITIES

There were no purchases of quoted securities during the financial period under review.

B 8. STATUS OF CORPORATE PROPOSALS

There is no corporate proposal announced but not completed as at the date of this report.

STEMLIFE BERHAD
(Company No: 566770-D)
Incorporated in Malaysia

B 9. STATUS OF UTILISATION OF LISTING PROCEEDS

StemLife Berhad (“StemLife” or the “Company”) was listed on the ACE Market (formerly known as the MESDAQ Market) on 17 October 2006. The Company raised RM13.2 million from its Initial Public Offering (“IPO”) and the details of utilisation of such proceeds as at 31 March 2010 is as follows:

Purpose	Proposed Utilisation RM'000	Initial Timeframe for Utilisation	Actual Utilisation RM'000	Balance of Amount Allocated RM'000	%	Extended Timeframe for Utilisation	Explanations
Third Laboratory	2,600	Within three (3) years from the date of Listing i.e. 17 October 2006 (“Date of Listing”)	-	2,600	100.0	By 31 March 2012	^ ##
Laboratory Equipments	3,000	Within three (3) years from Date of Listing	998	2,002	66.7	By 31 March 2012	^ ##
Logistics Expansion	600	Within three (3) years from Date of Listing	400	200	33.3	By 31 March 2010	^ ##
Branches Expansion	2,500	Within three (3) years from Date of Listing	637	1,863	74.5	By 17 October 2011	^ ##
Working Capital	2,500	-	2,998	(498)*	-	-	*
Listing Expenses	2,000	-	1,502	498*	-	-	*
	13,200		6,535	6,665	50.5		

Notes:

* The under utilisation of the listing expenses was adjusted to working capital and utilised fully in the 1st quarter 2007.

^ The approved timeframe for utilization is 3 years from the date of listing.

The Board of Directors had on 20 October 2009 approved and announced the extension of time for the utilisation of the balance of the IPO proceeds in the extended timeframe mentioned.

B 10. BORROWINGS AND DEBT SECURITIES

As at the current period under review, the Group does not have any borrowings and debt securities.

STEMLIFE BERHAD
(Company No: 566770-D)
Incorporated in Malaysia

B 11. OFF BALANCE SHEET FINANCIAL INSTRUMENTS

As at the date of this report, there are no off balance sheet financial instruments.

B 12. MATERIAL LITIGATIONS

As at the date of this report, there are no material litigations against StemLife and its subsidiary companies or taken by StemLife and its subsidiary companies except for the following:

- (1) Suit against Bristol Myers Squibb Sdn Bhd (“BMS”) and Arachnid Sdn Bhd (“ASB”)
 - (i) As reported earlier in the 2nd Quarter Report for the financial period ended 30 June 2008, the suit was filed by the Company in the Kuala Lumpur High Court on 22 May 2008 against BMS and ASB for defamatory articles posted on the MeadJohnson Sdn Bhd’s website. The Company has sought relief by way of an injunction and damages.
 - (ii) BMS and ASB have on 26 September 2008 and 28 October 2008 respectively filed applications to strike out the Company’s claim on, inter alia, the basis that it discloses no cause of action against them. The Company’s solicitors have filed Affidavits in Reply to the said applications on 30 January 2009.
 - (iii) BMS had also on 3 November 2008 amended its Statement of Defence and Counter Claim. As the amendment has no significant effect on the Company’s cause of action and its claim against BMS, the Company’s solicitors have not filed any amendments to the Company’s Reply to Defence and Counterclaim.
 - (iv) At the scheduled hearing of the suit for case management of BMS and ASB’s applications to strike out the Company’s claim on 17 February 2009, the Court directed as follows:
 - (a) In respect of ASB’s striking out application, counsels for both ASB and the Company are to file written submissions on 3 April 2009 and the hearing of the applications be fixed for 21 April 2009.
 - (b) With regard to BMS’s striking out application, the hearing is now fixed for 23 July 2009.
 - (v) The Company’s suit against ASB was struck off by the High Court on 21 April 2009. The Company has appealed against the said decision on 30 April 2009.
 - (vi) At the hearing of BMS’s application on 23 July 2009 the High Court struck out the Company’s suit against it. The Company has on 31 July 2009 filed an appeal against the said decision.
 - (vii) The Court of Appeal has scheduled 16 August 2010 for hearing of both the appeals against ASB and BMS respectively.
- (2) Suit against Cryocord Sdn Bhd (“CC”) and Esther Ho Sea Wai (“EH”)
 - (i) The Company had on 11 September 2008 filed a suit in the Kuala Lumpur High Court for injunction and damages against CC and EH for defamatory statements made against the Company.

STEMLIFE BERHAD

(Company No: 566770-D)

Incorporated in Malaysia

- (ii) The Company's solicitors have effected service of the Writ and Statement of Claim against CC's addresses on 12 and 13 November 2008. EH had been served with the Writ and Statement of Claim on 19 November 2008.
 - (iii) The solicitors for CC and EH had filed their Statement of Defence on 6 January 2009. The Company's solicitors have filed its Reply to Defence on 20 February 2009.
 - (iv) The hearing of the case management of the matter is fixed for 29 May 2009.
 - (v) At the hearing of the case management on 29 May 2009, the High Court directed the parties to prepare bundle of documents and pleadings, statements of agreed facts and issues to be tried. It has fixed 11 September 2009 for the hearing of the 2nd case management of the suit.
 - (vi) The Court has fixed 19 July 2010 for further case management.
- (3) Suit against Tan Yen Nee ("TYN") and Cellsafe International Sdn Bhd ("CSI")
- (i) The Company had filed a suit in the Kuala Lumpur High Court on 11 August 2008 against CSI and TYN for injunction and damages for defamatory statements made against the Company.
 - (ii) The Company had filed an amendment to its Statement of Claim on 17 October 2008. The amended Writ and Statement of Claim was served on CSI and TYN on 12 and 13 November 2008 respectively.
 - (iii) The solicitors for TYN and CSI have filed an application to strike out the Company's claim and for leave to defer the filing of Statement of Defense pending the disposal of the striking out application. The solicitors for the Company have filed its affidavit in reply on 20 February 2009. The hearing is scheduled for 1 April 2009 and the Court directed the parties to finalise all affidavits by 19 May 2009.
 - (iv) On 19 May 2009, the case management of TYN and CSI's application to strike out was scheduled for 5 August 2009.
 - (v) On 5 August 2009, the High Court directed the parties to prepare and hand over their respective written submissions on 15 September 2009 and scheduled the hearing date of TYN and CSI's application to strike out for 8 October 2009.
 - (vi) TYN and CSI's application to strike out the Company's claim was dismissed with costs by the Court on 16 October 2009. The Company solicitors are taking the necessary actions to apply for case management for the matter.

B 13. DIVIDENDS

No dividends were declared during the financial quarter under review or the financial period year to date.

STEMLIFE BERHAD
(Company No: 566770-D)
Incorporated in Malaysia

B 14. LOSS PER SHARE (“LPS”)

i. Basic LPS

The basic LPS is calculated by dividing the net earnings attributable to shareholders for the period by the weighted average number of ordinary shares in issue during the period.

	Current Year Quarter 31.03.2010 (RM'000)	Current Year To Date 31.03.2010 (RM'000)
Net Loss Attributable to Ordinary Shareholders	478	478
Weighted Average Number of Ordinary Shares of RM0.10 each in Issue ('000s)	165,000	165,000
Basic Loss per Share (sen)	0.29	0.29

ii. Diluted EPS

The company does not have any convertible shares or convertible financial instruments for the current financial quarter and financial year to date.

B 15. AUTHORISED FOR ISSUE

The interim financial statements were authorized for issue by the Board of Directors of StemLife in accordance with a resolution of the directors dated 25 May 2010.

By Order of the Board

Laang Jhe How (MIA 25193)
 Company Secretary
 26 May 2010